Top

Published in:

01-04-2014 | Clinical Trial

Germline variants in the CYP19A1 gene are related to specific adverse events in aromatase inhibitor users: a substudy of Dutch patients in the TEAM trial

Authors: Duveken B. Y. Fontein, Daniel Houtsma, Johan W. R. Nortier, Renee F. Baak-Pablo, Elma Meershoek-Klein Kranenbarg, Tahar R. J. H. M. van der Straaten, Hein Putter, Caroline Seynaeve, Hans Gelderblom, Cornelis J. H. van de Velde, Henk-Jan Guchelaar

Published in: Breast Cancer Research and Treatment | Issue 3/2014

Abstract

Musculoskeletal adverse events (MSAEs) and vasomotor symptoms (VMSs) are known side-effects of aromatase inhibitors, and may be related to genetic variations of the aromatase gene (CYP19A1). We investigated the relationship between these specific AEs and single nucleotide polymorphisms (SNPs) in the CYP19A1 gene in postmenopausal, hormone receptor-positive early breast cancer (BC) patients treated with adjuvant exemestane for 5 years. Dutch patients who were randomized to receive 5 years of exemestane in the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial were included. A tagging-SNP approach was performed, covering 80 % of variations of the CYP19A1 gene with 30 SNPs. Logistic regression analyses were used to assess the risk of reporting VMSs or MSAEs in relation to genotypes within selected SNPs. Of 737 included patients, 281 patients reported at least one MSAE (n = 210) or VMS (n = 163). Homozygous AA genotype of rs934635 was associated with a significantly higher odds of MSAEs (multivariate odds ratio (OR) 4.66, p = 0.008) and VMSs (multivariate OR 2.78, p = 0.044). Regarding both rs1694189 and rs7176005, the homozygous variant genotypes (TT) were associated with a higher odds of VMSs, but not MSAEs (OR 1.758, p = 0.025 and OR 6.361, p = 0.021, respectively). Our exploratory analysis demonstrated that some CYP19A1 gene variations may be associated with MSAEs and/or VMSs. Specifically, patients with the homozygous variant rs934635 genotype reported more MSAEs and VMSs. Although further confirmatory studies are warranted, genomic profiling can help identify patients at an increased risk of reporting these specific AEs, potentiating further personalized BC treatment.

Available only for authorised users

Rugo HS (2008) The breast cancer continuum in hormone-receptor-positive breast cancer in postmenopausal women: evolving management options focusing on aromatase inhibitors. Ann Oncol 19(1):16–27PubMedCrossRef

James VH, Reed MJ, Purohit A (1992) Inhibition of oestrogen synthesis in postmenopausal women with breast cancer. J Steroid Biochem Mol Biol 43(1–3):149–153PubMedCrossRef

Morales L, Pans S, Paridaens R, Westhovens R, Timmerman D, Verhaeghe J et al (2007) Debilitating musculoskeletal pain and stiffness with letrozole and exemestane: associated tenosynovial changes on magnetic resonance imaging. Breast Cancer Res Treat 104(1):87–91PubMedCrossRef

Mortimer JE (2010) Managing the toxicities of the aromatase inhibitors. Curr Opin Obstet Gynecol 22(1):56–60PubMedCrossRef

Morales L, Pans S, Verschueren K, Van CB, Paridaens R, Westhovens R et al (2008) Prospective study to assess short-term intra-articular and tenosynovial changes in the aromatase inhibitor-associated arthralgia syndrome. J Clin Oncol 26(19):3147–3152PubMedCrossRef

Kanematsu M, Morimoto M, Honda J, Nagao T, Nakagawa M, Takahashi M et al (2011) The time since last menstrual period is important as a clinical predictor for non-steroidal aromatase inhibitor-related arthralgia. BMC Cancer 11:436PubMedCentralPubMedCrossRef

Stearns V, Ullmer L, Lopez JF, Smith Y, Isaacs C, Hayes D (2002) Hot flushes. Lancet 360(9348):1851–1861PubMedCrossRef

Cuzick J, Sestak I, Cella D, Fallowfield L (2008) Treatment-emergent endocrine symptoms and the risk of breast cancer recurrence: a retrospective analysis of the ATAC trial. Lancet Oncol 9(12):1143–1148PubMedCrossRef

Fontein DB, Seynaeve C, Hadji P, Hille ET, van de Water W, Putter H et al (2013) Specific adverse events predict survival benefit in patients treated with tamoxifen or aromatase inhibitors: an international tamoxifen exemestane adjuvant multinational trial analysis. J Clin Oncol 31(18):2257–2264PubMedCrossRef

10.

Haiman CA, Dossus L, Setiawan VW, Stram DO, Dunning AM, Thomas G et al (2007) Genetic variation at the CYP19A1 locus predicts circulating estrogen levels but not breast cancer risk in postmenopausal women. Cancer Res 67(5):1893–1897PubMedCrossRef

11.

Talbott KE, Gammon MD, Kibriya MG, Chen Y, Teitelbaum SL, Long CM et al (2008) A CYP19 (aromatase) polymorphism is associated with increased premenopausal breast cancer risk. Breast Cancer Res Treat 111(3):481–487PubMedCrossRef

12.

Kristensen VN, Harada N, Yoshimura N, Haraldsen E, Lonning PE, Erikstein B et al (2000) Genetic variants of CYP19 (aromatase) and breast cancer risk. Oncogene 19(10):1329–1333PubMedCrossRef

13.

Dunning AM, Dowsett M, Healey CS, Tee L, Luben RN, Folkerd E et al (2004) Polymorphisms associated with circulating sex hormone levels in postmenopausal women. J Natl Cancer Inst 96(12):936–945PubMedCrossRef

14.

Wang L, Ellsworth KA, Moon I, Pelleymounter LL, Eckloff BW, Martin YN et al (2010) Functional genetic polymorphisms in the aromatase gene CYP19 vary the response of breast cancer patients to neoadjuvant therapy with aromatase inhibitors. Cancer Res 70(1):319–328PubMedCentralPubMedCrossRef

15.

Van de Velde CJ, Rea D, Seynaeve C, Putter H, Hasenburg A, Vannetzel JM et al (2011) Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial. Lancet 377(9762):321–331PubMedCrossRef

16.

Baak-Pablo R, Dezentje V, Guchelaar HJ, van der Straaten T (2010) Genotyping of DNA samples isolated from formalin-fixed paraffin-embedded tissues using preamplification. J Mol Diagn 12(6):746–749PubMedCentralPubMedCrossRef

17.

Wilkins K, LaFramboise T (2011) Losing balance: Hardy–Weinberg disequilibrium as a marker for recurrent loss-of-heterozygosity in cancer. Hum Mol Genet 20(24):4831–4839PubMedCentralPubMedCrossRef

18.

McWhinney SR, McLeod HL (2009) Using germline genotype in cancer pharmacogenetic studies. Pharmacogenomics 10(3):489–493PubMedCentralPubMedCrossRef

19.

van Huis-Tanja L, Kweekel D, Gelderblom H, Koopman M, Punt K, Guchelaar HJ et al (2013) Concordance of genotype for polymorphisms in DNA isolated from peripheral blood and colorectal cancer tumor samples. Pharmacogenomics 14(16):2005–2012PubMedCrossRef

20.

Goeman J, Solari A (2011) Multiple Testing for exploratory Research. Stat Sci 26(4):584–597CrossRef

21.

Burstein HJ (2007) Aromatase inhibitor-associated arthralgia syndrome. Breast 16(3):223–234PubMedCrossRef

22.

Key T, Appleby P, Barnes I, Reeves G (2002) Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst 94(8):606–616PubMedCrossRef

23.

Simpson ER (2003) Sources of estrogen and their importance. J Steroid Biochem Mol Biol 86(3–5):225–230PubMedCrossRef

24.

Straume AH, Knappskog S, Lonning PE (2012) Effect of CYP19 rs6493497 and rs7176005 haplotype status on in vivo aromatase transcription, plasma and tissue estrogen levels in postmenopausal women. J Steroid Biochem Mol Biol 128(1–2):69–75PubMedCrossRef

25.

Cai H, Shu XO, Egan KM, Cai Q, Long JR, Gao YT et al (2008) Association of genetic polymorphisms in CYP19A1 and blood levels of sex hormones among postmenopausal Chinese women. Pharmacogenet Genomics 18(8):657–664PubMedCentralPubMedCrossRef

26.

Ingle JN, Schaid DJ, Goss PE, Liu M, Mushiroda T, Chapman JA et al (2010) Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors. J Clin Oncol 28(31):4674–4682PubMedCentralPubMedCrossRef

27.

Napoli N, Rastelli A, Ma C, Yarramaneni J, Vattikutti S, Moskowitz G et al (2013) Genetic polymorphism at Val(80) (rs700518) of the CYP19A1 gene is associated with aromatase inhibitor associated bone loss in women with ER(+) breast cancer. Bone 55(2):309–314PubMedCrossRef

28.

Riancho JA, Valero C, Naranjo A, Morales DJ, Sanudo C, Zarrabeitia MT (2007) Identification of an aromatase haplotype that is associated with gene expression and postmenopausal osteoporosis. J Clin Endocrinol Metab 92(2):660–665PubMedCrossRef

29.

Miron L, Negura L, Peptanariu D, Marinca M (2012) Research on aromatase gene (CYP19A1) polymorphisms as a predictor of endocrine therapy effectiveness in breast cancer. Rev Med Chir Soc Med Nat Iasi 116(4):997–1004PubMed

30.

Mao JJ, Su HI, Feng R, Donelson ML, Aplenc R, Rebbeck TR et al (2011) Association of functional polymorphisms in CYP19A1 with aromatase inhibitor associated arthralgia in breast cancer survivors. Breast Cancer Res 13(1):R8PubMedCentralPubMedCrossRef

31.

Park IH, Lee YS, Lee KS, Kim SY, Hong SH, Jeong J et al (2011) Single nucleotide polymorphisms of CYP19A1 predict clinical outcomes and adverse events associated with letrozole in patients with metastatic breast cancer. Cancer Chemother Pharmacol 68(5):1263–1271

32.

Colomer R, Monzo M, Tusquets I, Rifa J, Baena JM, Barnadas A et al (2008) A single-nucleotide polymorphism in the aromatase gene is associated with the efficacy of the aromatase inhibitor letrozole in advanced breast carcinoma. Clin Cancer Res 14(3):811–816PubMedCrossRef

33.

Ghimenti C, Mello-Grand M, Grosso E, Scatolini M, Regolo L, Zambelli A et al (2013) Regulation of aromatase expression in breast cancer treated with anastrozole neoadjuvant therapy. Exp Ther Med 5(3):902–906PubMedCentralPubMed

Title: Germline variants in the CYP19A1 gene are related to specific adverse events in aromatase inhibitor users: a substudy of Dutch patients in the TEAM trial
Authors: Duveken B. Y. Fontein
Daniel Houtsma
Johan W. R. Nortier
Renee F. Baak-Pablo
Elma Meershoek-Klein Kranenbarg
Tahar R. J. H. M. van der Straaten
Hein Putter
Caroline Seynaeve
Hans Gelderblom
Cornelis J. H. van de Velde
Henk-Jan Guchelaar
Publication date: 01-04-2014
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 3/2014
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-014-2873-2

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2014

Primary breast tumor-derived cellular models: characterization of tumorigenic, metastatic, and cancer-associated fibroblasts in dissociated tumor (DT) cultures

A phase II, multicentre trial evaluating the efficacy of de-escalated bisphosphonate therapy in metastatic breast cancer patients at low-risk of skeletal-related events

Early treatment discontinuation and switching in first-line metastatic breast cancer: the role of patient-reported symptom burden

Surgical management of breast cancer in BRCA-mutation carriers: a systematic review and meta-analysis

Immune cell quantitation in normal breast tissue lobules with and without lobulitis

Recurrent mutation testing of BRCA1 and BRCA2 in Asian breast cancer patients identify carriers in those with presumed low risk by family history

Keynote webinar | Spotlight on antibody–drug conjugates in cancer